These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 28453784)

  • 1. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
    Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
    Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells.
    Choi D; Montermini L; Kim DK; Meehan B; Roth FP; Rak J
    Mol Cell Proteomics; 2018 Oct; 17(10):1948-1964. PubMed ID: 30006486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
    Koga T; Li B; Figueroa JM; Ren B; Chen CC; Carter BS; Furnari FB
    Neuro Oncol; 2018 Sep; 20(10):1310-1320. PubMed ID: 29660021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
    Lee M; Kang SY; Suh YL
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.
    van den Bent MJ; Gao Y; Kerkhof M; Kros JM; Gorlia T; van Zwieten K; Prince J; van Duinen S; Sillevis Smitt PA; Taphoorn M; French PJ
    Neuro Oncol; 2015 Jul; 17(7):935-41. PubMed ID: 25691693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 9. In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.
    Akbari H; Bakas S; Pisapia JM; Nasrallah MP; Rozycki M; Martinez-Lage M; Morrissette JJD; Dahmane N; O'Rourke DM; Davatzikos C
    Neuro Oncol; 2018 Jul; 20(8):1068-1079. PubMed ID: 29617843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly Sensitive EGFRvIII Detection in Circulating Extracellular Vesicle RNA of Glioma Patients.
    Batool SM; Muralidharan K; Hsia T; Falotico S; Gamblin AS; Rosenfeld YB; Khanna SK; Balaj L; Carter BS
    Clin Cancer Res; 2022 Sep; 28(18):4070-4082. PubMed ID: 35849415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
    Armocida D; Pesce A; Frati A; Santoro A; Salvati M
    J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short non-coding RNA sequencing of glioblastoma extracellular vesicles.
    de Mooij T; Peterson TE; Evans J; McCutcheon B; Parney IF
    J Neurooncol; 2020 Jan; 146(2):253-263. PubMed ID: 31912278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
    Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.
    Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A
    Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas.
    Manda SV; Kataria Y; Tatireddy BR; Ramakrishnan B; Ratnam BG; Lath R; Ranjan A; Ray A
    J Neurosurg; 2018 Apr; 128(4):1091-1101. PubMed ID: 28574310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
    Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
    Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
    Tykocinski ES; Grant RA; Kapoor GS; Krejza J; Bohman LE; Gocke TA; Chawla S; Halpern CH; Lopinto J; Melhem ER; O'Rourke DM
    Neuro Oncol; 2012 May; 14(5):613-23. PubMed ID: 22492960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
    Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
    Biernat W; Huang H; Yokoo H; Kleihues P; Ohgaki H
    Brain Pathol; 2004 Apr; 14(2):131-6. PubMed ID: 15193025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.